We investigated the additive therapeutic effect of the combination treatment of stroke with sub-therapeutic doses of Simvastatin, a HMG-CoA reductase inhibitor, and bone marrow stromal cells (BMSCs). Rats were administered Simvastatin (0.5 mg/kg), BMSCs (1 × 10 6 ) or combination of Simvastatin and BMSCs starting at 24 h after stroke. Combination treatment significantly improved neurological outcome, enhanced angiogenesis and arteriogenesis, and increased the number of engrafted-BMSCs in the ischemic brain. The number of engrafted-BMSCs and arteriogenesis was significantly correlated with functional outcome. Simvastatin significantly increased stromal cell-derived factor-1 (SDF1) expression in the ischemic brain and chemokine (CXC motif) receptor-4 (CXCR4) in BMSCs, and increased BMSC migration to RBMECs and astrocytes. Combination treatment of stroke upregulates the SDF1/CXCR4 axis and enhances BMSC migration into the ischemic brain, amplifies arteriogenesis and angiogenesis, and improves functional outcome after stroke.
Introduction
Stroke patients with higher density of cerebral blood vessels fare better and survive longer than those with lower vascular density (Wei et al., 2001) . Arteriogenesis and angiogenesis serve as efficient mechanisms to restore perfusion with oxygen and nutrition in the ischemic brain and promote long-term functional recovery in patients treated with or without thrombolysis for stroke (Christoforidis et al., 2005; Wei et al., 2001) . Therefore, stimulating arteriogenesis and angiogenesis may provide a treatment strategy for patients with stroke.
Adult bone marrow stromal cells (BMSCs) selectively target the injury site, participate in arteriogenesis and angiogenesis, and induce a neovascular response resulting in a significant increase in blood flow to the ischemic area which aids in repair of injured brain (Al-Khaldi et al., 2003; Chen et al., 2003a; Cui et al., 2008; Zacharek et al., 2007) . However, the effect of BMSC transplantation on stroke is dose-dependent (Borlongan et al., 2004; Chen et al., 2001) , and the success of a vascular route for BMSC treatment may be limited by the low migration efficiency of the transplanted-BMSCs into the lesioned area (Borlongan et al., 2004; Muller-Ehmsen et al., 2006) . Thus, strategies which promote BMSC migration into the ischemic brain may augment the BMSC regenerative treatment of stroke. Chemokines are important factors controlling cellular migration. Stromal cell-Derived Factor-1 (SDF1) and its unique receptor chemokine CXC motif receptor 4 (CXCR4) play an important role controlling cellular migration (Cui et al., 2007) .
Combining BMSCs and pharmacological therapy is an attractive approach for neurorestorative treatment of stroke (Chen and Chopp, 2006) . HMG-CoA reductase inhibitors (statins) are a class of drugs originally used to lower cholesterol. Statins also possess cholesterolindependent benefits including increasing vascular endothelial growth factor (VEGF), brain-derived neurogrowth factor (BDNF) expression and endothelial nitric oxide synthase (eNOS), and tissue plasminogen activator (tPA) activity, which augment cerebral blood flow, promote angiogenesis and improve functional outcome after stroke (Asahi et al., 2005; Chade et al., 2006; Chen et al., 2005 Chen et al., , 2003b . Our previous studies have shown that treatment of stroke with a therapeutic dose of Simvastatin (1 mg/kg) amplifies angiogenesis and vascular stabilization, and promotes arteriogenesis in rats (Chen et al., in press; Zacharek et al., 2007 Zacharek et al., , 2009 ). However, there are no studies, which evaluate whether combination treatment of stroke with sub-therapeutic doses of Simvastatin and BMSCs amplifies restorative therapy after stroke. In this study, we seek to test whether combination treatment of stroke with sub-therapeutic doses of Simvastatin and BMSCs induces additive functional improvement. We hypothesize, that Simvastatin promotes BMSC migration to the ischemic brain by upregulating SDF1/CXCR4 and increases arteriogenesis and angiogenesis, and thereby improves functional outcome. 
